Changzhou Qianhong Biopharma (002550) Fundamentals 2026 — P/E 25.7x, Revenue Analysis | SniperIQ
Changzhou Qianhong Biopharma (002550) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥8.2B, trading at ¥6.68 on the SHZ. This SniperIQ fundamentals page covers Changzhou Qianhong Biopharma's valuation (P/E 25.7x, P/B 2.9x), profitability (net margin 21.8%), revenue (¥1.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Changzhou Qianhong Biopharma's market cap?
Changzhou Qianhong Biopharma (002550) has a market capitalization of approximately ¥8.2B, trading at ¥6.68 on the SHZ. Market cap moves with the live share price.
What is Changzhou Qianhong Biopharma's P/E ratio?
Changzhou Qianhong Biopharma's trailing twelve-month P/E ratio is 25.7x, with a price-to-book (P/B) of 2.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Changzhou Qianhong Biopharma?
Changzhou Qianhong Biopharma runs a net profit margin of 21.8%, a gross margin of 60.2%, and an operating margin of 24.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Changzhou Qianhong Biopharma generate?
Changzhou Qianhong Biopharma reported revenue of ¥1.6B for fiscal year 2025, with net income of ¥399M and earnings per share (EPS) of 0.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Changzhou Qianhong Biopharma pay a dividend?
Changzhou Qianhong Biopharma offers a trailing dividend yield of about 2.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Changzhou Qianhong Biopharma financially healthy?
Changzhou Qianhong Biopharma carries a debt-to-equity ratio of 0.00x and a current ratio of 7.30x, with a market beta of 0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Changzhou Qianhong Biopharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Changzhou Qianhong Biopharma (002550) the key facts are: market cap ¥8.2B, P/E 25.7x, revenue ¥1.6B, 52-week range 5.58-11.97. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Changzhou Qianhong Biopharma's full fundamentals live
Get Changzhou Qianhong Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.